We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Loss of MicroRNA Induces Pro-Metastatic Changes in Pancreatic Cancer Cells

By LabMedica International staff writers
Posted on 14 Jun 2016
Reduced activity of a specific microRNA (miRNA) is apparent in chronically inflamed pancreatic tissue and in early stages of pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) even before tumor formation.

PDAC is characterized by very early metastasis, which has led some researchers to postulate that metastasis-associated changes may occur prior to actual tumor formation. More...
To confirm this hypothesis investigators at the German Cancer Research Center (Heidelberg, Germany) analyzed levels of miRNAs known to be linked to PDAC.

MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

The investigators reported in the May 23, 2016, online edition of the journal Cancer Research that they had identified the microRNA miR-192 as an epigenetically regulated suppressor gene with predictive value in PDAC. Levels of miR-192 were downregulated by promoter methylation in both PDAC and chronic pancreatitis (CP), a risk factor that leads to a 15-fold increase in the likelihood of contracting pancreatic cancer.

Functional studies in vitro and in mouse models of PDAC showed that overexpression of miR-192 was sufficient to reduce cell proliferation and invasion. Mechanistic analyses correlated changes in miR-192 promoter methylation and expression with epithelial-mesenchymal transition (EMT).

Cell proliferation and invasion were linked to altered expression of the miR-192 target gene SERPINE1, which encodes the protein plasminogen activator inhibitor-1 (PAI-1), an established regulator of these properties in PDAC cells. These results suggested that miR-192 downregulation established an invasive capacity in these pancreatic cells even before they transformed into cancer cells.

"We think that the cells often already have metastatic capacity before even transforming into cancer cells," said senior author Dr. Jörg Hoheisel, head of the division of functional genome analysis at the German Cancer Research Center. "To check this hypothesis, we searched the tumor cells for molecular changes that are indicative of the tendency to spread early. Our interpretation of these results is that epigenetic changes that occur already in inflamed pancreatic tissue lead to reduced production of miR-192. This means that the cells acquire the capacity of invasion and metastasis, which initially has no consequences. The actual transformation into cancer cells is caused by other, unrelated factors and can occur later. The result is cancer cells that are capable, from the very start, to invade surrounding tissue and spread metastases."

Related Links:
German Cancer Research Center


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.